GGrantIndex
← Leaderboards

Renda Soylemez Wiener

Va Boston Health Care System

$1,542,263
Attributed
$2,906,954
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $835.3K · FY200925
$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$2,906,954 · 2
VA$0 · 7

By mechanism

K12$2,047,036 · 1
K07$859,918 · 1
I01$0 · 5
I21$0 · 2

Most similar at Va Boston Health Care System

Same institution · by research overlap

Others in their field

Top investigators on “Learning

Research focus

LearningSiteVeteransAffectGuidelinesProgramsCaringDesignVariantFutureInterviewCessation Of LifeTrainingDecision MakingHealthcareMalignant Neoplasm Of LungShared Decision MakingRecommendationEvaluationPreferenceProviderBaseAmericanAged

Grant awards (27)

Co-Design and Pilot Testing of Peer-led Community Outreach to Improve Equity, Veteran-Centeredness and Uptake of Lung Cancer Screening$0
I21 · FY2025 · VA · contact PI
Prediction Augmented Screening Initiative$0
I01 · FY2025 · VA
CHOIR Summer Research Program (CHOIR-SRP)$0
I01 · FY2025 · VA
Impact of COVID-19 on implementation and outcomes of VA's Life-Sustaining TreatmentDecisions Initiative$0
I01 · FY2024 · VA
Co-Design and Pilot Testing of Peer-led Community Outreach to Improve Equity, Veteran-Centeredness and Uptake of Lung Cancer Screening$0
I21 · FY2024 · VA · contact PI
Impact of COVID-19 on implementation and outcomes of VA's Life-Sustaining TreatmentDecisions Initiative$0
I01 · FY2024 · VA
Impact of COVID-19 on implementation and outcomes of VA's Life-Sustaining TreatmentDecisions Initiative$0
I01 · FY2022 · VA
K12 Cardiopulmonary Implementation Science Scholars Program$386,120
K12 · FY2021 · HL
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension$0
I01 · FY2021 · VA · contact PI
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension$0
I01 · FY2021 · VA · contact PI
Achieving appropriate, safe, and patient-centered lung cancer screening$0
I01 · FY2021 · VA · contact PI
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension$0
I01 · FY2021 · VA · contact PI
K12 Cardiopulmonary Implementation Science Scholars Program$825,598
K12 · FY2020 · HL
Achieving appropriate, safe, and patient-centered lung cancer screening$0
I01 · FY2020 · VA · contact PI
Achieving appropriate, safe, and patient-centered lung cancer screening$0
I01 · FY2020 · VA · contact PI
K12 Cardiopulmonary Implementation Science Scholars Program$835,318
K12 · FY2019 · HL
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension$0
I01 · FY2019 · VA · contact PI
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension$0
I01 · FY2019 · VA · contact PI
Achieving appropriate, safe, and patient-centered lung cancer screening$0
I01 · FY2019 · VA · contact PI
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension$0
I01 · FY2019 · VA · contact PI
Progressing towards implementation of lung cancer screening in the VHA$0
I21 · FY2015 · VA · contact PI
Improving decisions about evaluating pulmonary nodules for lung cancer$169,236
K07 · FY2013 · CA · contact PI
Improving decisions about evaluating pulmonary nodules for lung cancer$169,236
K07 · FY2012 · CA · contact PI
Improving decisions about evaluating pulmonary nodules for lung cancer$169,236
K07 · FY2011 · CA · contact PI
Improving decisions about evaluating pulmonary nodules for lung cancer$169,236
K07 · FY2010 · CA · contact PI
Improving decisions about evaluating pulmonary nodules for lung cancer$169,027
K07 · FY2009 · CA · contact PI
Improving decisions about evaluating pulmonary nodules for lung cancer$13,947
K07 · FY2009 · CA · contact PI